

**Question for written answer E-003436/2022
to the Commission**

Rule 138

Christine Anderson (ID)

Subject: Conditions for liability of the Member States with regard to COVID-19 vaccines – Part 2

Further to the answer to the previous question P-002950/2022,¹ the Commission does not indicate in this answer the specific conditions under which Member States have to indemnify the manufacturers for possible liabilities.

It cites protection of the commercial interests of a natural or legal person as one of the reasons for refusing access to documents.

1. This approach means that the circumstances under which liability risks were transferred from companies to the respective national budgets, and the ceilings involved, are to remain unknown; is this compatible with the budgetary rules of both Parliament and the Member States?
2. Have there already been any cases involving COVID-19 vaccines in which liability has been acknowledged?
3. What level of reserves has already been included or has yet to be included in the budgets of the Member States for the corresponding liability risks?

¹ https://www.europarl.europa.eu/doceo/document/P-9-2022-002950_EN.html